What GHK-Cu actually does, why injectable GHK-Cu has no human trials, the copper biology behind the claims, and the real risks of research vials.
40 min read
GHK-Cu is sold as a peptide that rebuilds collagen, regrows hair, heals tendons and reverses ageing. This guide separates what the molecule can do in a dish, what it did in animals, what small topical trials showed on human skin, and what has actually been demonstrated when it is injected. Its central finding is uncomfortable but important: for the injectable route, the human evidence is not weaker than for creams, it is absent. Every claim carries an evidence grade and the route it was tested by, because mechanism, human trials and forum anecdotes are not interchangeable.
What's Inside
Written for adults who are weighing GHK-Cu, especially the injectable form, and want the evidence graded honestly rather than sold to them. It assumes you understand the difference between a cell culture result, an animal study and a human trial, and that you will involve a clinician before experimenting with anything. It is not a protocol, it is not medical advice, and it will not claim GHK-Cu does anything no human trial has shown.
GHK is a three-amino-acid peptide, glycyl-histidyl-lysine, first isolated from human plasma by Loren Pickart in 1973. It occurs naturally in plasma, saliva and urine, and is released when matrix proteins break down during tissue injury. GHK-Cu is the complex it forms with copper, which it binds about as tightly as albumin does, the chemical basis for the idea that it shuttles copper into cells. That copper matters: it is the cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and for antioxidant enzymes. In cell culture and animal wounds, GHK-Cu raised collagen synthesis, shifted inflammatory signalling and increased blood vessel growth. The widely repeated claim that natural GHK levels fall by more than half between ages 20 and 60 traces to a single unreplicated thesis figure, and even if exact, it would not tell you what an injected dose does.
Nobody knows, because the studies have never been done. No human trial has characterised injected GHK-Cu's pharmacokinetics, tested a dose-response, measured an efficacy endpoint or reported long-term safety. The strongest human evidence is topical: small, short, mostly industry-run facial cream trials reporting modest firmness and wrinkle changes, and one diabetic ulcer trial. Wound healing is the best-supported area overall, but only with local application in animals and people. Hair growth has been shown only in mice and macaques, and no tendon or ligament study exists in any species, so "GHK-Cu heals tendons" is borrowed from wound biology. A cream result also cannot be carried across to a syringe, because a local outcome after local delivery says nothing about whether an injected dose reaches another tissue at an effective level. The Peptide Database grades GHK-Cu against the same evidence standard.
Injectable safety has not been studied at any dose or duration, so "no reports of harm" on a forum is not a safety dataset. The specific concern is copper: the gut normally regulates how much copper enters the body, and every injected dose bypasses that control, yet no GHK-Cu study of any route has ever measured serum copper or ceruloplasmin. The guide is explicit about who should not experiment at all: anyone with Wilson disease or another copper-metabolism disorder, unexplained high copper, significant liver disease, pregnancy or breastfeeding, active or recent cancer, or anyone under 18. It also separates common injection-site stinging, which is not a sign of authenticity, from stop signals: fever or chills after a dose, which suggests endotoxin contamination, spreading redness, hives or swelling, and jaundice or dark urine. Baseline copper, ceruloplasmin, zinc and liver markers are worth discussing with a clinician, and the Bloodwork Analyzer reads the panel.
You cannot tell from the vial. Identity, potency, purity and sterility are four separate properties, and a vial can pass one and fail three. Mass spectrometry confirms identity, quantitative HPLC confirms how many milligrams are actually present, HPLC purity shows the share of the main peak, and sterility plus an endotoxin test confirms it is safe to inject, each on the specific lot. A blue colour only proves copper is present, and "research use only" is a supply-chain label, not a quality standard. Community reports get a proportionate look too: the two most common reports in the guide's sample were an adverse effect and no effect at all, and positive photos are heavily confounded by retinoids, weight loss and other peptides. The Peptide Stack Builder checks how GHK-Cu interacts with anything else you run.
The full guide covers the copper biology, the mechanism map, the full benefit ledger with a grade and route for every claim, the injectable evidence problem, the experimental dosing landscape, safety and copper homeostasis, monitoring, sourcing, a community reality check, myths, FAQs and red flags in detail. Download the PDF for the complete reference.
This page and the full guide are for educational purposes only. They are not medical advice, a prescription or a recommendation to use GHK-Cu. GHK-Cu is not an approved drug anywhere, injectable use has never been tested in a human trial, and regulatory status is changing and differs by country, so verify it locally. Any dosing discussed in the PDF describes community and experimental use, not a validated protocol. Do not start, stop or change any medication or compound without a qualified clinician. This content is not for anyone under 18, pregnant or breastfeeding, or with a copper-metabolism disorder, liver disease or a cancer history.
No human trial has tested injected GHK-Cu for any outcome. The benefits come from cell, animal and small topical studies, which cannot be carried across to an injection.
That comparison has never been studied. For the injectable route, the human evidence is not weaker than topical, it simply does not exist.
Its injectable safety has never been studied, and each dose adds copper past the gut's normal regulation. People with copper-metabolism disorders, liver disease, a cancer history or a pregnancy should not experiment at all.
No. Blue only shows copper is present; identity, amount and sterility each need their own lab test on that specific lot.
This guide is for educational purposes only and is not medical advice.
Newsletter
One email when a new guide, calculator or breakdown goes live. Nothing else.
